357337-00-9 Usage
Description
Brivaracetam (alfaR, 4R)-Isomer, also known as αR-Brivaracetam, is a racetam derivative with anticonvulsant properties. It is a 4-n-propyl analog of levetiracetam and is used as a reagent for the preparation of 2-Oxo-1-pyrrolidine derivatives, which possess anticonvulsant activity. This isomer is also recognized as an impurity in Brivaracetam (B677645), a medication used to treat epilepsy.
Uses
Used in Pharmaceutical Industry:
Brivaracetam (alfaR, 4R)-Isomer is used as a reagent for the preparation of 2-Oxo-1-pyrrolidine derivatives, which are known for their anticonvulsant properties. This application is crucial in the development of new medications to treat epilepsy and other seizure disorders.
Additionally, as an impurity in Brivaracetam (B677645), the alfaR, 4R)-Isomer plays a role in the overall effectiveness and safety profile of the medication. Understanding and controlling the presence of this isomer in the final product is essential for ensuring the therapeutic benefits and minimizing potential side effects for patients with epilepsy.
Check Digit Verification of cas no
The CAS Registry Mumber 357337-00-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,7,3,3 and 7 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 357337-00:
(8*3)+(7*5)+(6*7)+(5*3)+(4*3)+(3*7)+(2*0)+(1*0)=149
149 % 10 = 9
So 357337-00-9 is a valid CAS Registry Number.
357337-00-9Relevant articles and documents
Identification, characterization, synthesis and strategy for minimization of potential impurities observed in the synthesis of brivaracetam
Liao, Shouzhu,Chen, Hongjun,Wang, Guifei,Wu, Shuming,Yang, Zaiyou,Luo, Weihe,Liu, Zhuanfeng,Gao, Xun,Qin, Junhai,Li, Chuan-hua,Wang, Zhongqing
, (2020/05/25)
A first systematic impurity profile research concerning nine observed and potential process related impurities of antiepileptic drug brivaracetam is reported. Among which three (impurity G/H/I) have not been discovered or reported before, these nine impurities were monitored by HPLC, and their structures were identified on the basis of MS and NMR spectroscopy. In addition to the formation, synthesis, and characterization, strategies for minimizing these impurities to the levels accepted by ICH are also described in this report.
Process for the preparation of 2-oxo-1-pyrrolidine derivatives
-
Page/Page column 25, (2010/11/27)
The present invention relates to alternative processes for the preparation of 2-oxo-1-pyrrolidine derivatives of formula (I) Particularly, the present invention relates to alternative processes for the synthesis of levetiracetam, brivaracetam and seletracetam.
